Disrupting this pathway by blocking PD-1 receptors on immune cells or PD-L1 ligands on tumor and/or immune cells has emerged as a promising strategy for inhibiting tumor growth and potentially achieving a curative effect. This evidence concerns the gene CD274 and neoplasm.